



Biosketch:

Colette Côté, PhD, U.S. General Manager and Chief Scientific and Portfolio Officer at PathoQuest

Colette Côté joined PathoQuest as US General Manager and Chief Scientific and Portfolio Officer in March 2021. Prior to joining PathoQuest, Colette was the Director and Head of NGS R&D Testing Services at MilliporeSigma. Over the past 17 years, Colette has used her expertise and long history of innovating, developing, and applying tailored NGS-based assays to the biosafety testing space with a goal to expand and grow NGS far beyond its early applications, with a view towards the future.

Abstract:

“Biopharmaceuticals Animal-free Viral Assessment”

Next-Generation Sequencing (NGS) has reshaped the way biologics are tested for adventitious agents—offering an agnostic, animal-free approach that accelerates timelines and improves the safety of biologics. With the recent updates to global regulatory guidance documents endorsing its use, NGS is now well positioned to be a critical and central component of any biosafety testing strategy. This talk will provide essential details and case studies on how to implement, simplify, improve, and expand the adoption of innovative, globally accepted NGS-based biosafety solutions for your own pipelines. More importantly, this talk will provide insight into current regulatory expectations for NGS applications, specifically, what are they asking and why?